Claims for Patent: 9,241,998

Summary for Patent: 9,241,998

Title:	Methods and compositions for treatment of cancer using oncolytic RSV activity
Abstract:	The present invention relates generally to methods and compositions employing the oncolytic activity of respiratory syncytial virus (RSV) to treat cancer and other neoplastic disorders.
Inventor(s):	Bose; Santanu (Helotes, TX), Chatterjee; Bandana (San Antonio, TX)
Assignee:	Board of Regents, The University of Texas System (Austin, TX)
Application Number:	12/601,030
Patent Claims:	1. A method of treating a prostate neoplasm in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby treating the prostate neoplasm in the subject. 2. A method of treating a prostate cancer in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby treating the prostate cancer in the subject. 3. A method of reducing metastasis of a primary prostate cancer in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby reducing metastasis of the primary prostate cancer in the subject. 4. A method of reducing tumor size and/or tumor burden in a subject comprising a prostate tumor, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby reducing tumor size and/or tumor burden in the subject. 5. A method of inducing apoptosis of a prostate neoplastic or tumor cell in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby inducing apoptosis of the prostate neoplastic or tumor cell in the subject. 6. A method of reducing pain caused by a prostate tumor in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby reducing pain caused by the prostate tumor in the subject. 7. A method of increasing the sensitivity of a prostate tumor cell to radiation, comprising infecting the prostate tumor cell with a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby increasing the sensitivity of the prostate tumor cell to radiation. 8. A method of increasing the sensitivity of a prostate tumor cell to a chemotherapeutic agent, comprising infecting the prostate tumor cell with a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby increasing the sensitivity of the prostate tumor cell to a chemotherapeutic agent. 9. A method of sensitizing a prostate tumor cell to an immune response against RSV, comprising infecting the prostate tumor cell with a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, whereby the respiratory syncytial virus expresses respiratory syncytial virus antigen on the surface of the prostate tumor cell, thereby sensitizing the prostate tumor cell to an immune response against respiratory syncytial virus. 10. A method of treating a prostate tumor or neoplasm in a subject, comprising removing the prostate tumor or neoplasm from the subject and administering to the subject an oncolytic amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby treating a prostate tumor or neoplasm in the subject. 11. A method of reducing the likelihood of recurrence of a prostate tumor or neoplasm in a subject, comprising removing the prostate tumor or neoplasm from the subject and administering to the subject an oncolytic amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby reducing the likelihood of recurrence of a prostate tumor or neoplasm in the subject. 12. A method of eliminating or reducing the number of neoplastic prostate cells in an ex vivo population of neoplastic prostate cells and normal prostate cells, comprising contacting the population with a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, under conditions whereby the respiratory syncytial virus can infect the prostate cells and kill the neoplastic prostate cells, thereby eliminating or reducing the number of neoplastic prostate cells in the ex vivo population. 13. The method of claim 4, wherein the respiratory syncytial virus (RSV) has a mutation in a gene selected from the group consisting of the NS1, NS2, N, P, M, SH, G, F, M2-1/M2-2, and L genes, and any combination thereof. 14. The method of claim 4, further comprising administering an immunosuppressive agent, a chemotherapeutic agent, an immunostimulatory agent, radiation, or any combination thereof, before, during and/or after administration of the RSV. 15. The method of claim 4, wherein the immunosuppressive agent is selected from the group consisting Azathioprine, Alefacept, Anakinra, Anti-lymphocyte globulin, Anti-thymocyte globulin, Ascomycin, Auranofin, Aurothioglucose, Azathioprine, Basiliximab, CNTO 1275, Ciclosporin (Cyclosporine), Cortisol, Cyclic steroids, Daclizumab, Disodium aurothiomalate, Etanercept, Everolimus, Gliotoxin, Gold salts, Gusperimus, Leflunomide, Mercaptopurine, Methotrexate, Mycophenolic acid, Natalizumab, Penicillamine, Pimecrolimus, Prednisone, Rapamycin, Sirolimus, Sodium aurothiomalate, Sulfasalazine, Tacrolimus, and natural anti-cancer herbal agents, and any combination thereof. 16. The method of claim 14, wherein the chemotherapeutic agent is selected from the group consisting of Anti-estrogens, Anthracyclins, Azacitidine, Azathioprine, Bleomycin, Busulfan, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Dacarbazine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Epothilone, Etoposide, 5-Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Imatinib, Interferons, Mechlorethamine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin C, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Retinoic acid, Taxol, Taxotere, Tamoxifen, Teniposide, Thiotepa, Tioguanine, Valrubicin, Vinblastine, Vincristine, Vindesine, and Vinorelbine, and any combination thereof. 17. The method of claim 14, wherein the immunostimulatory agent is selected from the group consisting of immunostimulatory cytokines, oligodeoxynucleotide (ODN), CpG, cytotoxic/apoptotic/suicides genes and proteins, immuno-stimulatory genes and proteins, and any combination thereof. 18. The method of claim 14, wherein the radiation is gamma radiation. 19. The method of claim 4, wherein the prostate tumor is a solid prostate tumor. 20. The method of claim 2, wherein the prostate cancer is metastatic prostate cancer. 21. The method of claim 4, wherein the prostate tumor is a primary prostate tumor. 22. The method of claim 4, wherein the prostate tumor is a metastatic prostate tumor. 23. The method of claim 4, wherein the tumor size is in a range from about 2 cm to about 30 cm. 24. The method of claim 4, wherein the RSV is delivered directly to the tumor either at a single site or at multiple sites. 25. The method of claim 4, wherein the RSV is delivered to the subject systemically. 26. The method of claim 4, wherein the RSV is administered continuously over a period of time. 27. The method of claim 4, wherein the RSV is administered at intervals of every hour, every two hours, every three hours, every day, every other day, every three days, every week, and/or every month. 28. The method of claim 4, wherein the dose of RSV is administered in a range from about 1.times.10.sup.2 pfu/ml to about 1.times.10.sup.8 pfu/ml of virus particles. 29. The method of claim 4, wherein the subject is selected from the group consisting of humans, nonhuman primates, dogs, cats, horses, cattle, and livestock. 30. The method of claim 4, wherein the RSV is a live purified RSV. 31. The method of claim 4, wherein the RSV is an attenuated RSV. 32. The method of claim 4, wherein the RSV is selected from the group consisting of bovine RSV, human RSV, and any combination thereof. 33. The method of claim 4, wherein the RSV is a human RSV. 34. The method of claim 4, wherein the RSV is bovine RSV. 35. The method of claim 4, further comprising administering one or more different oncolytic viruses, before, during and/or after administration of the RSV, wherein the one or more oncolytic viruses is selected from the group consisting of either nonengineered or engineered adenovirus, reovirus, herpesvirus, Newcastle disease virus, vaccinia virus, measles virus, Coxsackie virus, vesicular stomatitis virus, parvovirus, influenza virus, and Rabbit myxoma virus, and any combination thereof.

Details for Patent 9,241,998

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2027-05-21
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998		2027-05-21
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	01/02/2003		2027-05-21
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2027-05-21
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2027-05-21
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2027-05-21